IDH1 and central nervous system cancer: IDH1 point mutations, most commonly R132H, drive > 80% of lower grade gliomas and secondary glioblastomas by catalyzing the neomorphic production of the oncometabolite D-2-hydroxyglutarate (D2HG) from αKG [1,2,3].